WO2007132790A1 - 細菌菌体成分を含む脂質膜を有するリポソーム - Google Patents
細菌菌体成分を含む脂質膜を有するリポソーム Download PDFInfo
- Publication number
- WO2007132790A1 WO2007132790A1 PCT/JP2007/059782 JP2007059782W WO2007132790A1 WO 2007132790 A1 WO2007132790 A1 WO 2007132790A1 JP 2007059782 W JP2007059782 W JP 2007059782W WO 2007132790 A1 WO2007132790 A1 WO 2007132790A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ribosome
- bcg
- lipid
- peptide
- lipid membrane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
Definitions
- Ribosomes with lipid membranes containing bacterial cell components Ribosomes with lipid membranes containing bacterial cell components
- the present invention relates to a liposome having a lipid membrane containing a bacterial cell component insoluble in water and an organic solvent, and a pharmaceutical composition containing the ribosome.
- betaters and carriers for reliably delivering drugs, nucleic acids, peptides, proteins, sugars and the like to target sites has been actively conducted.
- viral vectors such as retroviruses, adenoviruses, and adeno-associated viruses have been developed as vectors for introducing a target gene into target cells.
- virus vectors have problems such as difficulty in mass production, antigenicity, and toxicity
- ribosome vectors and peptide carriers with few such problems are attracting attention.
- Liposome vectors also have the advantage that the directivity to the target site can be improved by introducing functional molecules such as antibodies, proteins, and sugar chains on the surface.
- BCG Mycobacterium bovis bacillus Calmette—Guerin, attenuated bovine tuberculosis
- BCG Mycobacterium bovis bacillus Calmette—Guerin, attenuated bovine tuberculosis
- This tumor regression effect is considered to be due to the so-called tumor immunotherapy effect that cell immunity is activated by the powerful adjuvant (immunostimulation) action of BCG.
- BCG-CW Bacterial cell components against this side-effect problem
- BCG-CW Bacterial cell components against this side-effect problem
- bacterial cell components such as BCG-CW are insoluble in water and organic solvents because of their special structure and physicochemical properties.
- it since it has a negative charge, it has a problem that the efficiency of uptake into a cell having a low affinity with a cell membrane having the same negative charge is low.
- bacterial cell components such as BCG-CW need to be soluble by surfactants, but side effects such as stimulation by surfactants can be problematic, and bacteria solubilized by surfactants can be problematic. Since the bacterial cell component has a large particle size (about 300 nm or more) and is negatively charged, the efficiency of cellular uptake is still low, and the problem still remains.
- Patent Document 1 International Publication WO2005Z032593 Pamphlet
- Non-patent literature l Kogure et al., “Journal of Controlled Release”, 2004, 98 ⁇ , 317-323
- Non-Patent Document 2 Rikiru Ikurami et al., RYAKUGAKU ZASSHIJ, 2004, 124 ⁇ , Suppl. 4, 1 13-116
- a bacterial cell component insoluble in water and an organic solvent can be applied to a living body without using a surfactant (dispersible in an aqueous solvent, It is an object of the present invention to provide a ribosome that can be formulated into a size-controlled form) and a pharmaceutical composition containing the liposome.
- the present invention provides a ribosome having a lipid membrane containing a bacterial cell component insoluble in water and an organic solvent, and a pharmaceutical composition containing the ribosome.
- a bacterial cell component insoluble in water and an organic solvent can be applied to a living body without using a surfactant (a form that can be dispersed in an aqueous solvent and has a controlled size). ) Can be formulated.
- the bacterial cell component is a cell wall fraction of Mycobacterium, Nocardia, Corynebata, or Rhodococcus. It is preferable that the Mycobacterium having a cell wall skeletal fraction is BCG.
- the ribosome of the present invention preferably has a peptide containing a plurality of continuous arginine residues on the ribosome surface.
- the ribosome of the present invention can be transferred into cells mainly via macrophage pinosis, so that bacterial cell components insoluble in water and organic solvents can be efficiently introduced into cells. it can.
- the peptide is preferably a peptide having a force of 4 to 35 amino acid residues including a continuous 4 to 20 arginine residue.
- the peptide has only an arginine residue.
- the amount of the peptide is preferably 2% (molar ratio) or more with respect to the total lipid constituting the ribosome.
- the peptide is modified with a hydrophobic group or a hydrophobic compound, and the hydrophobic group or the hydrophobic compound is inserted into a lipid membrane forming the surface of the ribosome.
- the peptide is exposed from the lipid membrane that forms the surface of the ribosome! /.
- the bacterial cell component has an immunostimulatory action
- the pharmaceutical composition is an immunostimulatory agent.
- a bacterial cell component insoluble in water and an organic solvent can be applied to a living body without using a surfactant (dispersible in an aqueous solvent and has a size.
- a surfactant dispenserible in an aqueous solvent and has a size.
- Is provided in a controlled form), and pharmaceutical compositions containing the liposomes are provided.
- FIG. 1 is a diagram showing the structure of a functional domain included in BCG-CW.
- FIG. 2 is a diagram showing the results of observation with a confocal laser microscope.
- FIG. 3 is a diagram showing the results of observation with a confocal laser microscope.
- FIG. 5 shows intracellular localization of R8-modified BCG ribosome incorporated into MBT-2.
- FIG. 6 is a diagram showing the measurement results of the activity of rod cells using CD86, CD80 and MHCII as indices.
- the ribosome of the present invention is a closed vesicle having a lipid membrane (lipid bilayer membrane), and the number of lipid membranes possessed by the liposome of the present invention is not particularly limited.
- the ribosome of the present invention may be a multilamellar ribosome (MLV), or a single-film rifonosome such as SUV (small unilamellar vesicle), LUV (large unilamellar vesicle), or GUV giant unilamellar vesicle. May be.
- the size of the ribosome of the present invention is not particularly limited, but a diameter of 50 to 300 nm is preferable, and a diameter of 100 to 200 nm is more preferable.
- lipid membrane examples include lipids, membrane stabilizers, antioxidants, charged substances, membrane proteins, and the like.
- Lipid is an essential constituent of the lipid membrane, and the amount of lipid contained in the lipid membrane is usually 70% (molar ratio) or more, preferably 75% (molar ratio) of the total amount of the substance constituting the lipid membrane. ) Or more, more preferably 80% (molar ratio) or more.
- the upper limit of the amount of lipid contained in the lipid membrane is 100% of the total amount of substances constituting the lipid membrane.
- lipids examples include phospholipids, glycolipids, sterols, saturated or unsaturated fatty acids exemplified below.
- Phosphatidylcholine eg, dioleoylphosphatidylcholine, dilauroylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, etc.
- phosphatidylglycerol eg, dioleoylphosphatidylglycerol, dilauroylphosphatidylglycerol, dilauroylphosphatidylcholine
- Myristoylphosphatidylglycerol dipalmitoylphosphatidylglycerol , Distearoyl phosphatidylglycerol, etc.
- phosphatidylethanolamine eg, dilauroyl phosphatidylethanolamine, dimyristoyl phosphatidylethanolamine, dipalmitoyl phosphatidylethanolamine, di
- Glycose glycolipid for example, sulfoxyribosyl glyceride, diglycosyl diglyceride, digalactosyl diglyceride, galactosyl diglyceride, glycosyl diglyceride), Sphingo glycolipid (for example, galactosyl celeb oral side, latatosyl celeb oral side, gandarioside), etc.
- Animal-derived sterols eg, cholesterol, cholesterol succinic acid, cholestanol, lanostero monore, dihydrolanostero monore, desmostero monore, dihydrocholesterol
- plant-derived sterols eg, stigmasterol, Sitosterol, campesterol, brassicasterol
- sterols derived from microorganisms eg, timosterol, ergosterol.
- Saturated or unsaturated fatty acids having 12 to 20 carbon atoms such as normitic acid, oleic acid, stearic acid, arachidonic acid and myristic acid.
- the membrane stabilizer is an optional component of the lipid membrane that can be included to physically or chemically stabilize the lipid membrane or to regulate the fluidity of the lipid membrane.
- the amount of membrane stabilizer contained in the lipid membrane is usually 30% (molar ratio) or less, preferably 25% (molar ratio) or less, more preferably 20% (molar ratio) of the total amount of substances constituting the lipid membrane. ) Note that the lower limit of the content of the membrane stabilizer is zero.
- Examples of the film stabilizer include sterol, glycerin or fatty acid esters thereof. Can be mentioned. Specific examples of the sterol are the same as those described above, and examples of the glycerin fatty acid ester include triolein and trioctanoin.
- the antioxidant is an optional component of the lipid membrane that can be contained to prevent lipid membrane acidification, and the amount of antioxidant contained in the lipid membrane is Is usually 30% (molar ratio) or less, preferably 25% (molar ratio) or less, and more preferably 20% (molar ratio) or less.
- the lower limit of the antioxidant content is 0.
- antioxidants examples include tocopherol, propyl gallate, ascorbyl palmitate, butylated hydroxytoluene and the like.
- the charged substance is an optional component of the lipid membrane that can be contained to impart positive charge or negative charge to the lipid membrane, and the amount of the charged substance contained in the lipid membrane is determined by the lipid membrane. It is usually 30% (molar ratio) or less, preferably 25% (molar ratio) or less, and more preferably 20% (molar ratio) or less of the total amount of the substances constituting the above. The lower limit of the charged substance content is zero.
- Examples of the charged substance imparting a positive charge include saturated or unsaturated aliphatic amines such as stearylamine and oleylamine; saturated or unsaturated cationic synthetic lipids such as dioleoyltrimethylammonium propane and the like.
- Examples of the charged substance that imparts a negative charge include dicetyl phosphate, cholesteryl hemisuccinate, phosphatidylserine, phosphatidylinositol, and phosphatidic acid.
- a membrane protein is an optional component of a lipid membrane that can be contained in order to maintain the structure of the lipid membrane or to impart functionality to the lipid membrane, and is contained in the lipid membrane.
- the amount of membrane protein is usually 10% (molar ratio) or less, preferably 5% (molar ratio) or less, more preferably 2% (molar ratio) or less of the total amount of substances constituting the lipid membrane.
- the lower limit of the membrane protein content is zero.
- membrane proteins include membrane surface proteins and membrane integral proteins.
- lipid constituting the lipid membrane a lipid derivative having a blood retention function, a temperature change sensitivity function, a pH sensitivity function, or the like may be used.
- one or more of the above functions can be imparted to the ribosome.
- Retention mechanism in blood in ribosome By imparting the ability, the retention of ribosomes in the blood can be improved, and the capture rate by reticuloendothelial tissues such as the liver and spleen can be reduced.
- the ribosome a temperature change-sensitive function and a Z- or PH-sensitive function, the release of the target substance encapsulated in the ribosome can be enhanced.
- Examples of the blood-retaining lipid derivative capable of imparting the blood-retaining function include, for example, glycophorin, gandarioside GM1, phosphatidylinositol, gandarioside GM3, glucuronic acid derivative, glutamic acid derivative, and polyglycerin phospholipid derivative.
- Examples of the temperature change sensitive lipid derivative capable of imparting a temperature change sensitive function include dipalmitoylphosphatidylcholine and the like.
- Examples of the pH sensitive lipid derivative capable of imparting a pH sensitive function include, for example, di And oleoylphosphatidylethanolamine.
- the ribosome of the present invention has a lipid membrane containing bacterial cell components insoluble in water and organic solvents.
- bacterial cell components are contained in one lipid membrane of the ribosome, and when the ribosome is a multilamellar ribosome, one or more of the plurality of lipid membranes of the ribosome
- the lipid membrane contains bacterial cell components.
- the amount of bacterial cell components contained in the lipid membrane is usually 1 to 15% (weight ratio), preferably 2 to 10% (weight ratio), more preferably 3 to 7 of the total amount of substances constituting the lipid membrane. % (Weight ratio).
- Bacterial cell components are insoluble in water and organic solvents (eg, black mouth form, dichloroacetic acid, methanol, ethanol, ether, jetyl ether, hexane, tetrahydrofuran, etc.).
- organic solvents eg, black mouth form, dichloroacetic acid, methanol, ethanol, ether, jetyl ether, hexane, tetrahydrofuran, etc.
- cell wall fractions or cell wall skeleton fractions of Mycopacteria bacteria, Nocardia bacteria, Corynebatarum bacteria, Rhodococcus bacteria and the like can be mentioned as long as they are soluble.
- the cell wall of the genus Mycopacteria contains mycolic acid (fatty acid), arabinogalatatan (polysaccharide), and a polymer that has the power of peptide darlicans, and this polymer constitutes the basic structure of the cell wall. .
- This basic structure is called “Cell-Wall Skeleton (CWS)”.
- the composition and preparation method of the cell wall fraction are not particularly limited as long as the cell wall skeleton is the main component.
- the cell wall fraction can be prepared by the following method. Suspend the heated dead cells in 10 volumes of purified water and crush the cells by French press treatment. Subsequently, the cell disruption solution is centrifuged at 6760 X g to remove unbroken cells, and the centrifuged supernatant is further centrifuged at 18000 X g to obtain a cell wall fraction as a sediment.
- the median diameter of micelles formed by suspending a cell wall fraction (for example, BCG-CW) in water, buffer, etc. is usually 120 to 320 nm, preferably 170 to 270, more preferably 220. . The median diameter is measured with a particle size distribution meter, for example.
- the cell wall skeleton fraction is a fraction obtained by purifying the cell wall skeleton from the cell wall fraction, and can be prepared, for example, by the following method.
- the cells were suspended wall fraction in a phosphate buffer, thereby decomposing and removing the cell wall bound nucleic acid (e.g. oligo DNA) by DNase treatment, pronase (pronase) and trypsin (trypsin) decomposition to remove cell wall bound protein by treatment.
- the lipid is extracted and removed by extraction with an organic solvent (for example, tetrahydrofuran).
- an organic solvent for example, tetrahydrofuran
- the median diameter of micelles formed by suspending a cell wall skeletal fraction (for example, BCG-CWS) in water, a buffer solution or the like is usually 80 to 180 nm, preferably 100 to 150 nm, more preferably 130 nm.
- the median diameter is measured with a particle size distribution meter, for example.
- Mycobacterium bacteria, Nocardia bacteria, Corynebatarum bacteria, Rhodococcus The cell wall fraction or cell wall skeleton fraction of the genus bacteria and the like is insoluble in water and organic solvents and has an immune activation action (adjuvant activity, immunostimulation action).
- the peptide darican part and the mycolic acid part are important for immune activity.
- Components other than the cell wall skeleton contained in the cell wall fraction for example, lipomannan, trehalo monomycolate) also contribute to the immune activity.
- Mycobacterium bacteria include tuberculosis groups such as M. tuberculosis, M. bo vis, M. africanum, M. microti, M. canettii, and M. bovis BCG.
- Nocardia bacteria examples include N. asteroides, N. brasiliensis, and N. rubra.
- Corynebacterium bacteria examples include C. diphtheriae and C. ulcerans.
- BCG-CW cell wall fraction
- BCG-CWS cell wall skeleton fraction
- BCG is an attenuated bacterium produced by repeated laboratory cultures of Mycobacterium bovis, and is hardly pathogenic to humans.
- the functional domains contained in BCG CW or BCG-CWS include the structure shown in Fig. 1, lipomannan (LM), lipoarabinomannan (LAM), diphosphatidylinositol (PIM2) or hexamanoside (PIM6) and Contains code factor (TDM).
- the ribosome of the present invention preferably has a peptide containing a plurality of continuous arginine residues on its surface.
- the number of consecutive arginine residues is not particularly limited as long as it is plural, but it is usually 4 to 20, preferably 6 to 12, and more preferably 7 to 10.
- the total number of amino acid residues constituting the peptide is not particularly limited, but is usually 4 to 35, preferably 6 to 30, and more preferably 7 to 23. It is preferable that the peptide is capable of including an arbitrary amino acid sequence at the C-terminal and Z- or N-terminal of a plurality of consecutive arginine residues.
- the amino acid sequence added to the C-terminal or N-terminal of a plurality of consecutive arginine residues is preferably an amino acid sequence having rigidity (for example, polyproline).
- Polyproline is Unlike polyethylene glycol (PEG), which is soft and irregularly shaped, it is linear and retains a certain degree of rigidity.
- the amino acid residue contained in the amino acid sequence added to the C-terminal or N-terminal of a plurality of consecutive arginine residues is preferably an amino acid residue other than acidic amino acids. This is because an acidic amino acid residue having a negative charge may electrostatically interact with a positively charged arginine residue and attenuate the effect of the arginine residue.
- the amount of the peptide present on the surface of the ribosome is usually 0.1 to 30% (molar ratio), preferably 0.2 to 25% (molar ratio), more preferably the total lipid constituting the ribosome. 0.5 to 20% (molar ratio).
- the ribosome of the present invention can be transferred into the cell via the peptide present on the surface (WO2005Z032593). reference).
- the amount of peptide present on the surface of the ribosome Less than 2% (molar ratio), preferably less than 1.5% (molar ratio), more preferably less than 1% (molar ratio) based on the total lipid constituting the ribosome.
- the ribosome can be transferred into the cell mainly via endocytosis (see WO2005Z032593).
- the lower limit of the peptide amount at this time is usually 0.1% (molar ratio), preferably 0.5% (molar ratio), more preferably 0.7% (molar ratio) with respect to the total lipid constituting the ribosome. Ratio).
- the amount of peptide present on the surface of the ribosome is 2% (molar ratio) or higher, preferably 3% (molar ratio) or higher, more preferably 4% (molar ratio) or higher, with respect to the total lipid constituting the ribosome.
- Ribosomes can be transferred into cells mainly via macropinocytosis (see WO2005Z032593).
- the upper limit of the amount of peptide is usually 30% (molar ratio), preferably 25% (molar ratio), more preferably 20% (molar ratio) with respect to the total lipid constituting the ribosome.
- the ribosome In macropinocytosis, extracellular substances are taken up into cells as a fraction called macropinosome, and unlike macrosomes, macropinosomes do not fuse with lysosomes. Can be avoided. Therefore, when the liposome is transferred into the cell via macropinocytosis, the ribosome can be transferred into the cell efficiently. [0050] When the ribosome translocation pathway depends on endocytosis, the lipid membrane must contain cationic lipid as its main component, but the ribosome translocation pathway does not depend on endocytosis In some cases, it is not necessary for the lipid membrane to contain a cationic lipid, and the cytotoxicity due to the cationic lipid can be reduced.
- the ratio of the cationic lipid to the total lipid constituting the liposome is preferably 0 to 40% (molar ratio), and more preferably 0 to 20% (molar ratio).
- Examples of the cationic lipid include DODAC (dioctadecyldimethylammonium chlori de), DOTMA (N- (2,3-dioleyloxy) propyl-N, N, N-trimethylammonium), DDAB (did odecylammonium bromide), DOTAP (l , 2-dioleoyloxy- 3-trimethylammonio propane), DC— Choi (3 ⁇ — N— ( ⁇ ', ⁇ ', — dimethy) aminoethane) — carbamol cholesterol), DM RIE (1, 2-dimyristoyloxypropyl-3-dimethylhydroxyethyl ammonium ), DOSPA (2,3-dioleyloxy—N— [2 (sperminecarboxamido) ethyl] —N, N—dimethyl— 1—propanaminum trifluo roacetate), etc., and non-power thionic lipids (neutral
- a peptide containing a plurality of consecutive arginine residues is modified with a hydrophobic group or a hydrophobic compound, and the hydrophobic group or hydrophobic compound is inserted into the lipid membrane forming the surface of the ribosome.
- the peptide is preferably present on the surface of the ribosome by being exposed from the lipid membrane forming the surface of the ribosome.
- Peptides containing multiple consecutive arginine residues maintain a certain orientation and are present on the ribosome surface, so that liposomes can be efficiently transferred into cells via macropinocytosis. it can.
- the hydrophobic group or the hydrophobic compound is not particularly limited as long as it can be inserted into the lipid membrane.
- the lipid membrane is composed of a hydrophilic portion and a hydrophobic portion, and the hydrophobic group or the hydrophobic compound is inserted into the lipid membrane in a state of being hydrophobically bonded to the hydrophobic portion of the lipid membrane.
- a hydrophobic group examples thereof include saturated or unsaturated fatty acid groups such as stearyl groups, cholesterol groups or derivatives thereof, among which fatty acid groups having 10 to 20 carbon atoms (for example, normitoyl group, oleyl group, stearyl group). Group, arachidoyl group and the like).
- hydrophobic compound examples include phospholipids, glycolipids or sterols exemplified above, long-chain aliphatic alcohols (for example, phosphatidylethanolamine, cholesterol, etc.), polyoxypropylene alkyl, glycerin.
- long-chain aliphatic alcohols for example, phosphatidylethanolamine, cholesterol, etc.
- polyoxypropylene alkyl examples include fatty acid esters.
- the lipid that is a component of the lipid membrane, a predetermined bacterial cell component, and a predetermined peptide modified with a hydrophobic group or a hydrophobic compound are mixed, and the organic solvent is removed by evaporation.
- the organic solvent include hydrocarbons such as pentane, hexane, heptane, and cyclohexane; halogenated hydrocarbons such as methylene chloride and chloroform; aromatic carbonization such as benzene and toluene.
- the lipid membrane is hydrated, stirred or sonicated to produce a ribosome having a lipid membrane containing a predetermined bacterial cell component and having a predetermined peptide on the surface.
- a lipid that is a component of the lipid membrane and a predetermined bacterial cell component are mixed, and the organic solvent is evaporated and removed to obtain a lipid membrane.
- the lipid membrane is hydrated and stirred or superhydrated.
- a ribosome having a lipid membrane containing a predetermined bacterial cell component is produced.
- a predetermined peptide modified with a hydrophobic group or a hydrophobic compound is added to the external solution of the ribosome, and the predetermined peptide is introduced onto the ribosome surface.
- a ribosome having a certain particle size distribution By passing the ribosome through a filter having a predetermined pore size, a ribosome having a certain particle size distribution can be obtained.
- conversion to multilamellar liposome force single membrane ribosome and conversion to single membrane ribosome force multilamellar ribosome can be performed.
- a bacterial cell component without using a surfactant can be formulated into a form that can be applied to a living body (a form that can be dispersed in an aqueous solvent and has a controlled size).
- bacterial cell components can be efficiently introduced into the cell.
- the types of cells into which bacterial cell components should be introduced are not particularly limited. Examples include rod-shaped cells, macrophages (macrophages), ⁇ lymphocytes, mononuclear cells, polymorphonuclear leukocytes, and tumor cells. It is done.
- the pharmaceutical composition containing the ribosome of the present invention can be used for pharmaceutical use according to the action of bacterial cell components.
- the pharmaceutical composition containing the ribosome of the present invention can be used as an immunostimulator (adjuvant).
- the immune activator can activate humoral immunity (antibody production) and cellular immunity by activating immune cells such as rod-shaped cells (antigen-presenting cells).
- the immune activator may activate the immune cell by being taken up by the immune cell, or may activate the immune cell by acting on the external force of the immune cell.
- Examples of the dosage form of the pharmaceutical composition include a ribosome dispersion or a dried product thereof (eg, a lyophilized product, a spray-dried product, etc.).
- a ribosome dispersion or a dried product thereof eg, a lyophilized product, a spray-dried product, etc.
- the dispersion solvent for example, a buffer solution such as physiological saline, phosphate buffer solution, queen buffer solution, and acetate buffer solution can be used.
- additives such as sugars, polyhydric alcohols, water-soluble polymers, nonionic surfactants, antioxidants, pH adjusters, hydration accelerators may be added to the dispersion.
- the pharmaceutical composition can also be used in any case, both in vivo and in vitro.
- the administration route includes, for example, parenteral administration such as intravenous, intraperitoneal, subcutaneous, and nasal administration. It can be appropriately adjusted according to the amount and the like.
- ribosome suspension was prepared by rotating the rotary evaporator with air pressure (no vacuum).
- ImM rhodamine red
- the obtained ribosome suspension is permeated through the 0.8 m, 0.4 m, and 0.1 m membranes multiple times (etastruder treatment), so that ribosome with a small particle diameter (about 120 nm) Prepared.
- This ribosome has a lipid membrane containing BCG-CW and has STR-R8 on its surface (hereinafter referred to as “R8-modified BCG ribosome”).
- BCG-CW was prepared by Nippon Bijijichi Manufacturing Co., Ltd. using the following method. BCG heated dead cells were suspended in 10 volumes of purified water, and the cells were disrupted by French press treatment. Subsequently, the cell disruption solution was centrifuged at 6760 X g to remove unbroken cells, and the supernatant obtained by centrifuging the supernatant at 18000 X g was lyophilized to obtain BCG-CW.
- the median diameter of micelles formed by suspending BCG-CW thus obtained in purified water or the like is usually 120 to 320 nm, preferably 170 to 270 nm, more preferably 220 nm as measured with a particle size distribution meter. .
- Lipid? 701 0 1 7: 3 (molar ratio)) in a chloroform solution (lipid amount: 10 mol) and FTSC-labeled BCG—CW (BCG—CW amount) suspended in chloroform Z-ethanol (2: 1): 0.4 mg), and dried under reduced pressure on a rotary evaporator to prepare a lipid thin film containing BCG-CW but not STR-R8, and then treating in the same manner as above.
- Liposomes having a lipid membrane containing BCG—CW and no STR—R8 on the surface were prepared (hereinafter “R8 unmodified BCG ribosome” t).
- NIH3T3 cells 2.5 ⁇ 10 5 cells Z60 mm dish
- NIH3T 3 cells are then treated with blood containing R8 modified or unmodified BCG ribosomes (final lipid concentration 50 ⁇ ).
- Incubation was performed in a clean DMEM culture medium. Incubation was for 1 hour at 37 ° C. At the end of the incubation, the cells were washed and then observed with a confocal laser microscope without fixation.
- BCG ribosome or R8-modified BCG ribosome was added in an amount of 3.3 mg and cultured at 37 ° C for 1 hour. Analysis of the amount of intracellular fluorescence using flow cytometry (BD Biosciences) showed that the amount of intracellular fluorescence increased in the R8-modified BCG ribosome, and the increase in the amount of intracellular uptake by STR-8 modification was confirmed. (Fig. 4).
- STR-R8 solution (STR-R8 amount: the amount of lipid 0.8 or 5 moles 0/0) were mixed and vacuum dryness in a rotary evaporator, BCG CW and STR —
- a lipid thin film containing R8 was prepared and treated in the same manner as in Example 1 to prepare a ribosome having a lipid membrane containing BCG-CW and STR-R8 on the surface (the amount of STR-R8 was following what is 0.8 mol 0/0 of the amount of lipid is referred to as "low-density R8 qualified BCG ribosome", following what is 5 mol 0/0 and "high density R8 qualified BCG ribosome"!, U).
- Lipid? 701 0 1 7: 3 (molar ratio)) in a chloroform solution (lipid amount: 10 mol) and FTSC-labeled BCG—CW (BCG—CW amount) suspended in chloroform Z-ethanol (2: 1): 0.4 mg) and then dried under reduced pressure on a rotary evaporator to prepare a lipid film containing BCG-CW but not STR-R8, and then treating in the same manner as in Example 1. V and ribosomes having a lipid membrane containing BCG-CW and STR-R8 on the surface were prepared (hereinafter referred to as “R8 non-modified BCG ribosome”).
- Lipid? 701 0 1 7: 3 (molar ratio)) chloroform solution (lipid amount: 10 mol) and ST 1 ⁇ 1 ⁇ 8 aqueous solution (3 1 1 ⁇ 1 ⁇ 8 amount: 0.8 mol 0 of lipid amount) / 0 ) and drying under reduced pressure using a rotary evaporator, a lipid thin film containing STR-R8 but not BCG-CW is prepared and treated in the same manner as in Example 1.
- a ribosome having a lipid membrane not containing BCG-CW and having STR-R8 on its surface was prepared (hereinafter referred to as “low density R8-modified BCG-free ribosome”!).
- Lipid? Flip 701 0 1 7: 3 (molar ratio)) chloroform solution (the amount of lipid: 10 mol), under reduced pressure to dryness at mouth one rotary evaporator, 8 Ji 0 Ji 1 ⁇ ⁇ also 3-chome 1
- a lipid thin film not containing ⁇ 1 ⁇ 8 was prepared and treated in the same manner as in Example 1.
- a lipid membrane containing BCG-CW, a STR-R8 on the surface, and a ribosome containing BCG-CW were prepared. (Hereinafter referred to as “R8 non-modified BCG-free ribosome”!).
- Various ribosomes were added to a serum-free medium of rod-shaped cells (DC) isolated from mouse bone marrow, incubated at 37 ° C for 2 hours, and then cultured in the presence of serum for 22 hours. The presence or absence of activity was examined. As markers of DC activity, superficial marker proteins CD86 and CD80, and MHCII involved in antigen presentation, were selected. Using a fluorescent labeled antibody against each protein, a flow cytometer (FACS) was used to control the markers in each treatment group. The amount of protein per force was measured.
- DC rod-shaped cells
- Spider cells treated with modified BCG ribosomes ⁇ LowR8 Lip / BCG-CW '' are spider cells treated with low density R8 modified BCG ribosomes, ⁇ HighR8 Lip / BCG-CWJ are treated with high density R8 modified BCG ribosomes As shown in Fig. 5, high-density R8-modified BCG ribosome exerted high immune cell activity ability similar to LPS which is a typical adjuvant.
- the bladder cancer cell line MBT-2 (RIKEN) was cultured at 37 ° C, 5% CO. 7 week old C3HZ
- mice (Charles River) were divided into groups A to G, and 0.7 ⁇ 10 ⁇ MBT-2 and each of the following samples were transplanted on the right side of the back of each group of mice.
- Group A 100 ⁇ 1 PBS buffer (6 animals)
- Group B lmg BCG (BCG Corporation) ZlOO ⁇ 1 PBS buffer (6 mice)
- Group C lmg BCG prepared in Example 1—CWZ 100 ⁇ 1 PBS buffer (18 mice)
- Group D 0. lmg BCG—CWZlOO ⁇ 1 PBS buffer prepared in Example 1 (6 mice)
- Group E PBS buffer solution (18 mice) of R8-modified BCG-rich ribosome Z 100 ⁇ 1 having a lipid membrane containing lmg of BCG—CW prepared in Example 1 and STR-R 8 on the surface
- Group F 0. lmg BCG prepared in Example 1 with a lipid membrane containing CW and STR — R8 on the surface R8-modified BCG low ribosome ZlOO ⁇ 1 in PBS buffer (6 mice)
- Group G BCG — Without CW! /, With lipid membrane, STR—With no R8 on the surface! /, R8 unmodified BCG-free ribosome ZlOO ⁇ 1 in PBS buffer (6 mice)
- the above ribosome is the production of the low-density R8-modified BCG ribosome described in Example 2. In the method, it was prepared by changing the content of BCG-CW. The R8-unmodified BCG-free ribosome was prepared in the same manner as described in Example 2.
- mice After each group of mice was bred for 4 weeks, the tumor tissue derived from the transplanted cancer cells was excised and the size (mm 2 ) was measured to confirm the tumor regression effect of each sample. The results are shown in Table 1.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07743217A EP2027865A4 (en) | 2006-05-12 | 2007-05-11 | LIPOSOME HAVING A LIPIDIC MEMBRANE CONTAINING A BACTERIAL CELLULAR COMPONENT |
JP2008515540A JPWO2007132790A1 (ja) | 2006-05-12 | 2007-05-11 | 細菌菌体成分を含む脂質膜を有するリポソーム |
US12/300,622 US20100166840A1 (en) | 2006-05-12 | 2007-05-11 | Liposome having lipid membrane containing bacterial cell component |
CA002652475A CA2652475A1 (en) | 2006-05-12 | 2007-05-11 | Liposome having lipid membrane containing bacterial cell component |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006134526 | 2006-05-12 | ||
JP2006-134526 | 2006-05-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007132790A1 true WO2007132790A1 (ja) | 2007-11-22 |
Family
ID=38693882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/059782 WO2007132790A1 (ja) | 2006-05-12 | 2007-05-11 | 細菌菌体成分を含む脂質膜を有するリポソーム |
Country Status (5)
Country | Link |
---|---|
US (1) | US20100166840A1 (ja) |
EP (1) | EP2027865A4 (ja) |
JP (1) | JPWO2007132790A1 (ja) |
CA (1) | CA2652475A1 (ja) |
WO (1) | WO2007132790A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014034669A1 (ja) | 2012-08-28 | 2014-03-06 | 国立大学法人北海道大学 | 非極性溶媒に分散性を有する細菌菌体成分を内封する脂質膜構造体およびその製造方法 |
US9066971B2 (en) | 2010-07-01 | 2015-06-30 | Postech Academy-Industry Foundation | Method for treating and diagnosing cancer by using cell-derived microvesicles |
WO2018164116A1 (ja) * | 2017-03-06 | 2018-09-13 | 国立大学法人筑波大学 | リポソーム、抗癌剤及び癌治療用キット |
US20220175852A1 (en) * | 2019-04-24 | 2022-06-09 | Liaoning Greatest Bio-Pharmaceutical Co. Ltd. | Use of rhodococcus ruber product in treating thermal injury |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102185682B1 (ko) * | 2009-06-04 | 2020-12-11 | 고쿠리츠칸센쇼켄쿠죠 | 마이코플라즈마 감염증용 백신 |
JP5787323B2 (ja) * | 2010-04-28 | 2015-09-30 | 国立大学法人北海道大学 | 脂質膜構造体 |
CN103393597B (zh) * | 2013-07-02 | 2015-06-17 | 北京大学 | 疏水性肽修饰的注射用长循环脂质体给药系统 |
EP3440187A1 (en) * | 2016-04-07 | 2019-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use |
CN114533764A (zh) * | 2021-12-31 | 2022-05-27 | 苏州大学 | 一种脂质膜包被益生菌及其制备和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06507420A (ja) * | 1991-11-06 | 1994-08-25 | ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング (ゲー・ベー・エフ) | 粘膜の病原体に対するワクチンとその製法 |
JP2002529427A (ja) * | 1998-11-06 | 2002-09-10 | シュヴァイツ.ゼールム− ウント インプフインスティトゥート ベルン | 薬学的作用物質の調合物および投与器具 |
WO2004012751A1 (ja) * | 2002-08-02 | 2004-02-12 | Sumitomo Pharmaceuticals Company, Limited | 細菌細胞壁骨格成分製剤 |
WO2005032593A1 (ja) * | 2003-10-01 | 2005-04-14 | Japan Science And Technology Agency | 核移行能を有するポリアルギニン修飾リポソーム |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030180351A1 (en) * | 1998-11-06 | 2003-09-25 | Reinhard Gluck | Pharmaceutically active composition and dispensing device |
ES2231037B1 (es) * | 2003-10-31 | 2005-12-16 | Archivel Technologies, Sl | Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos. |
-
2007
- 2007-05-11 US US12/300,622 patent/US20100166840A1/en not_active Abandoned
- 2007-05-11 EP EP07743217A patent/EP2027865A4/en not_active Withdrawn
- 2007-05-11 CA CA002652475A patent/CA2652475A1/en not_active Abandoned
- 2007-05-11 WO PCT/JP2007/059782 patent/WO2007132790A1/ja active Application Filing
- 2007-05-11 JP JP2008515540A patent/JPWO2007132790A1/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06507420A (ja) * | 1991-11-06 | 1994-08-25 | ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング (ゲー・ベー・エフ) | 粘膜の病原体に対するワクチンとその製法 |
JP2002529427A (ja) * | 1998-11-06 | 2002-09-10 | シュヴァイツ.ゼールム− ウント インプフインスティトゥート ベルン | 薬学的作用物質の調合物および投与器具 |
WO2004012751A1 (ja) * | 2002-08-02 | 2004-02-12 | Sumitomo Pharmaceuticals Company, Limited | 細菌細胞壁骨格成分製剤 |
WO2005032593A1 (ja) * | 2003-10-01 | 2005-04-14 | Japan Science And Technology Agency | 核移行能を有するポリアルギニン修飾リポソーム |
Non-Patent Citations (5)
Title |
---|
BEAUDET, R. ET AL.: "Anti tumor activity of some BCG fractions incorporated in liposomes", MICROBIOS LETTERS, vol. 23, no. 90, 1983, pages 63 - 66, XP008123851 |
CHUGH, LB. ET AL.: "Immunoprotective behaviour of liposome entrapped cell wall subunit of Mycobacterium tuberculosis against experimental tuberculous infection in mice", EUROPEAN RESPIRATORY JOURNAL, vol. 6, no. 6, 1993, pages 811 - 815, XP008123748 |
KHALIL IKRAMY ET AL., YAKUGAKU ZASSHI, vol. 124, no. 4, 2004, pages 113 - 116 |
KOGURE ET AL., JOURNAL OF CONTROLLED RELEASE, vol. 98, 2004, pages 317 - 323 |
ROSENKRANDS I. ET AL.: "Cationic Liposomes Containing Mycobacterial Lipids: a New Powerful Th1 Adjuvant System", INFECTION AND IMMUNITY, vol. 73, no. 9, 2005, pages 5817 - 5826, XP003019330 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9066971B2 (en) | 2010-07-01 | 2015-06-30 | Postech Academy-Industry Foundation | Method for treating and diagnosing cancer by using cell-derived microvesicles |
WO2014034669A1 (ja) | 2012-08-28 | 2014-03-06 | 国立大学法人北海道大学 | 非極性溶媒に分散性を有する細菌菌体成分を内封する脂質膜構造体およびその製造方法 |
US9717687B2 (en) | 2012-08-28 | 2017-08-01 | National University Corporation Hokkaido University | Lipid membrane structure including bacterial cell component having dispersibility in non-polar solvent, and method for producing same |
WO2018164116A1 (ja) * | 2017-03-06 | 2018-09-13 | 国立大学法人筑波大学 | リポソーム、抗癌剤及び癌治療用キット |
JPWO2018164116A1 (ja) * | 2017-03-06 | 2020-01-30 | 国立大学法人 筑波大学 | リポソーム、抗癌剤及び癌治療用キット |
JP7220472B2 (ja) | 2017-03-06 | 2023-02-10 | 国立大学法人 筑波大学 | リポソーム、抗癌剤及び癌治療用キット |
US20220175852A1 (en) * | 2019-04-24 | 2022-06-09 | Liaoning Greatest Bio-Pharmaceutical Co. Ltd. | Use of rhodococcus ruber product in treating thermal injury |
Also Published As
Publication number | Publication date |
---|---|
JPWO2007132790A1 (ja) | 2009-09-24 |
CA2652475A1 (en) | 2007-11-22 |
EP2027865A1 (en) | 2009-02-25 |
EP2027865A4 (en) | 2010-08-18 |
US20100166840A1 (en) | 2010-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007132790A1 (ja) | 細菌菌体成分を含む脂質膜を有するリポソーム | |
KR101476167B1 (ko) | 약물 송달 제어용 경폐 투여 리포좀 | |
JP4628955B2 (ja) | 核移行能を有するポリアルギニン修飾リポソーム | |
EP1867726A1 (en) | Liposome capable of effective delivery of given substance into nucleus | |
WO2007037444A1 (ja) | 目的物質を核内又は細胞内に送達するためのベクター | |
WO2015079952A1 (ja) | アジュバント組成物およびこれを含むワクチン組成物、並びにこれらの製造方法 | |
WO2007102481A1 (ja) | 目的物質の核内送達用ベクター | |
WO2013140643A1 (ja) | 機能性タンパク質を細胞内に送達するためのキャリア | |
JPWO2008105178A1 (ja) | リポソーム用生体成分抵抗性増強剤及びこれにより修飾されたリポソーム | |
US9717687B2 (en) | Lipid membrane structure including bacterial cell component having dispersibility in non-polar solvent, and method for producing same | |
JPWO2006077857A1 (ja) | 粒子を脂質膜で被覆する方法 | |
JP2006238839A (ja) | 核酸の細胞内送達効率又は細胞内発現効率を向上させた組成物 | |
US20100136099A1 (en) | Liposome for induction of cell-mediated immunity | |
WO2012153616A1 (ja) | 標的細胞移行能を有する脂質膜構造体、その製造方法および標的細胞において効果を示す物質のスクリーニング方法 | |
JP4450656B2 (ja) | リポソームからなる遺伝子導入用キャリア | |
JP2007166946A (ja) | 標的遺伝子の発現を抑制するための組成物 | |
WO2009131216A1 (ja) | オリゴアルキレングリコールで修飾された脂質膜構造体 | |
JP2014114267A (ja) | 脂質膜構造体に対して肝臓血管内皮細胞への移行能を付与および/または増強するペプチド、肝臓血管内皮細胞への移行能を有するまたは肝臓血管内皮細胞への移行能が増強された脂質膜構造体、ならびに脂質膜構造体に対して肝臓血管内皮細胞への移行能を付与および/または増強する剤 | |
WO2018164116A1 (ja) | リポソーム、抗癌剤及び癌治療用キット | |
WO2012117971A1 (ja) | 脂質膜構造体、脂質膜構造体の製造方法および1の目的物質を1枚の脂質膜で封入する方法 | |
能崎優太 | Rational Design of Liposome-Based Immunity-Inducing System for Cancer Immunotherapy | |
Demana | ISCOMs and related colloidal particles prepared by the lipid film hydration method for antigen delivery | |
JP2009286709A (ja) | ゴルジ装置ターゲティング用リポソーム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07743217 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008515540 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2652475 Country of ref document: CA Ref document number: 12300622 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007743217 Country of ref document: EP |